Ionetix

Ionetix (Ionetix Corporation) is an American radioisotope and radiopharmaceutical technology company founded in 2009 from technology developed at the MIT Plasma Science and Fusion Center. The company describes itself as a cyclotron and technology company providing full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. Its core technical achievement is the ION-12SC, which Ionetix describes as the world's first commercial compact superconducting cyclotron. The ION-12SC is used to produce N-13 Ammonia, a PET imaging agent used for the detection of coronary artery disease (CAD). Ionetix is building a network of ION-12SC cyclotrons installed on or near the campuses of PET programs across the United States. Under its business model, Ionetix covers the costs of installation and ongoing operation of the cyclotron and makes N-13 Ammonia available to providers through a pay-by-the-dose model, aiming to make the tracer accessible and affordable to providers nationwide. More recently, Ionetix has been leveraging its growing network of radiopharmaceutical manufacturing locations to support the development and commercialization of targeted alpha therapy (TAT). TAT is an emerging cancer therapy that uses alpha radionuclides to deliver high-energy alpha particles to cancer cells and the tumor microenvironment while preserving healthy tissue. The company markets therapeutic alpha radionuclides for use in TAT from a new facility, alongside its cyclotron, cGMP, and operational solutions. Ionetix positions itself at the intersection of clinical excellence and business opportunity, offering PET educational resources such as a PET Educational Series and cardiac PET practice materials. Its quality policy commits the company to the design, manufacturing, and support of safe and effective radiopharmaceutical products that meet or exceed customer, medical professional, user, and regulatory expectations. The company operates primarily in the United States and is privately held.

Ionetix was founded in 2009 from technology born at the MIT Plasma Science and Fusion Center. The company developed the ION-12SC, which it describes as the world's first commercial compact superconducting cyclotron. This cyclotron is used to produce N-13 Ammonia, a PET imaging agent for the detection of coronary artery disease (CAD). Ionetix has pursued a network strategy: it is actively establishing a network of ION-12SCs installed on or near the campus of PET programs across the United States. By covering all costs related to the installation and ongoing operation of the cyclotron and making N-13 Ammonia available to providers through a pay-by-the-dose model, the company aims to make this critical tracer accessible and affordable to providers nationwide. More recently, Ionetix has leveraged its growing network of radiopharmaceutical manufacturing locations to support the development and commercialization of targeted alpha therapy (TAT). TAT is an emerging cancer therapy utilizing alpha radionuclides that delivers high-energy alpha particles to cancer cells and the tumor microenvironment to treat cancer while preserving healthy tissue. The company has opened a new facility for TAT products and markets therapeutic alpha radionuclides for use in targeted alpha therapy. Ionetix also provides cyclotron solutions, operational solutions, and cGMP solutions, and offers educational resources including a PET Educational Series for cardiac PET practice. Its quality policy states a commitment to the design, manufacturing, and support of safe and effective radiopharmaceutical products meeting or exceeding customer, medical professional, user, and applicable regulatory expectations.

• 2009

  Ionetix founded from technology born at the MIT Plasma Science and Fusion Center.

• Developed the ION-12SC, described as the world's first commercial compact superconducting cyclotron.

• Established a network of ION-12SC cyclotrons installed on or near PET program campuses across the United States.

• Opened a new facility for therapeutic alpha radionuclides for targeted alpha therapy.

Full-service radioisotope production and end-to-end radiopharmaceutical manufacturing, with a pay-by-the-dose model for N-13 Ammonia and an emerging focus on targeted alpha therapy.

• ION-12SC compact superconducting cyclotron

  Described as the world's first commercial compact superconducting cyclotron, used to produce N-13 Ammonia.

• N-13 Ammonia

  A PET imaging agent for the detection of coronary artery disease (CAD), offered through a pay-by-the-dose model.

• Targeted alpha therapy (TAT) radionuclides

  Therapeutic alpha radionuclides for use in targeted alpha therapy, an emerging cancer therapy.

1. 1Ionetix | Leading Radiopharmaceuticals & Targeted Alpha Therapyionetix.com
2. 2About - Ionetixionetix.com
3. 3Ionetix Corporation - Wikidatawikidata.org